605507.SH
国邦医药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 15.38
−1.28%Year over year
Reported trailing growth
- Revenue
- +1.7%
- EBITDA
- —
- EBIT
- -0.4%
- EPS
- -3.2%
- Free cash flow
- +671.6%
- Operating cash flow
- +154.5%
Forward estimates
Based on analyst estimates
- Revenue
- -76.4%
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +1.7%
- EBITDA
- +3.1%
- EBIT
- -2.9%
- Net income
- -3.8%
- EPS
- -3.6%
- Free cash flow
- +9.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026